| Dr Raul M Arroyo, MD | |
|
Arecibo Medical Plaza, Ave. Barbosa # 65 Suite # 105, Arecibo, PR 00612-2746 | |
| (787) 878-5785 | |
| (787) 817-5288 |
| Full Name | Dr Raul M Arroyo |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 30 Years |
| Location | Arecibo Medical Plaza, Arecibo, Puerto Rico |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104926807 | NPI | - | NPPES |
| $$$$$$$$$ | Other | PR | SSN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 11492 (Puerto Rico) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hospital Dr Susoni Inc | Arecibo, PR | Hospital |
| Entity Name | Raul Arroyo Rosario Md C S P |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295083665 PECOS PAC ID: 7315199692 Enrollment ID: O20121213000146 |
News Archive
Today's headlines include reports about how the presidential election's outcome could impact the insurance industry as well as the fate of people who are sick or uninsured.
A rare, small RNA turns a gene-splicing machine into a switch that controls the expression of hundreds of human genes. Howard Hughes Medical Institute Investigator and professor of Biochemistry Gideon Dreyfuss, PhD, and his team from the Perelman School of Medicine at the University of Pennsylvania, discovered an entirely new aspect of the gene-splicing process that produces messenger RNA (mRNA).
A new study published in the American Journal of Respiratory and Critical Care Medicine shows that recording the way the organisms living within the lungs change in type and numbers could reflect the response of the critically ill patient to medical care. Though changes in the lung microbiome have been known to exist even before this study, this research shows the clinical importance of this test.
In order to colonize other organs and grow into metastases, tumor cells that detach from the parent tumor need to manipulate their new microenvironment and create a 'metastatic niche'.
OncoGenex Pharmaceuticals, Inc. announced today publication of results from a randomized Phase 2 trial in the Journal of Clinical Oncology. The trial results showed a survival benefit with the investigational agent OGX-011/TV1011 (custirsen) in patients with advanced prostate cancer. The median overall survival for patients who were treated with custirsen plus first-line docetaxel/prednisone was 23.8 months compared to 16.9 months for patients treated with docetaxel/prednisone alone.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Raul M Arroyo, MD Po Box 142774, Arecibo, PR 00614-2774 Ph: (787) 878-5785 | Dr Raul M Arroyo, MD Arecibo Medical Plaza, Ave. Barbosa # 65 Suite # 105, Arecibo, PR 00612-2746 Ph: (787) 878-5785 |
News Archive
Today's headlines include reports about how the presidential election's outcome could impact the insurance industry as well as the fate of people who are sick or uninsured.
A rare, small RNA turns a gene-splicing machine into a switch that controls the expression of hundreds of human genes. Howard Hughes Medical Institute Investigator and professor of Biochemistry Gideon Dreyfuss, PhD, and his team from the Perelman School of Medicine at the University of Pennsylvania, discovered an entirely new aspect of the gene-splicing process that produces messenger RNA (mRNA).
A new study published in the American Journal of Respiratory and Critical Care Medicine shows that recording the way the organisms living within the lungs change in type and numbers could reflect the response of the critically ill patient to medical care. Though changes in the lung microbiome have been known to exist even before this study, this research shows the clinical importance of this test.
In order to colonize other organs and grow into metastases, tumor cells that detach from the parent tumor need to manipulate their new microenvironment and create a 'metastatic niche'.
OncoGenex Pharmaceuticals, Inc. announced today publication of results from a randomized Phase 2 trial in the Journal of Clinical Oncology. The trial results showed a survival benefit with the investigational agent OGX-011/TV1011 (custirsen) in patients with advanced prostate cancer. The median overall survival for patients who were treated with custirsen plus first-line docetaxel/prednisone was 23.8 months compared to 16.9 months for patients treated with docetaxel/prednisone alone.
› Verified 1 days ago
Dr. Fernando A Arroyo-gonzalez, MD Urology Medicare: Medicare Enrolled Practice Location: Carretera 129 Km 1.0, Ave San Luis, Arecibo, PR 00613 Phone: 787-650-7272 |